WEB DESK: Researchers may have uncovered a promising new strategy to slow the progression of Alzheimer’s disease by enhancing the ability of brain cells to repair their DNA. This groundbreaking finding was published in FEBS Open Bio and conducted by scientists at King’s College London. The team tested an experimental compound, KCL-286, on mice with Alzheimer’s, suggesting that targeting DNA damage could represent a novel therapeutic pathway.
Traditional treatments mainly focus on alleviating symptoms or decelerating the disease’s progress without addressing its fundamental causes. Over time, brain cells accumulate DNA damage due to factors such as aging, inflammation, and normal cellular processes. When this damage surpasses the brain’s repair capacity, neurons may begin to malfunction or die, contributing to cognitive decline.
The study centered on a protein called retinoic acid receptor-beta (RARβ), which plays a key role in controlling gene expression. KCL-286 activates this receptor, initiating a mechanism that enhances the production of proteins responsible for DNA repair. Following treatment, the mice exhibited improved DNA repair within their neurons, along with reductions in brain inflammation and abnormal immune activity linked to Alzheimer’s.
Professor Jonathan Corcoran compared this process to fixing potholes—once repaired, traffic flows more smoothly. Similarly, repairing DNA damage in neurons can restore cellular function and reduce harmful inflammation in the brain.
The researchers are optimistic that this approach could eventually be applied to treat Alzheimer’s and other neurodegenerative diseases. Since DNA damage is a common feature in various neurological disorders, boosting the brain’s natural repair systems could have wide-ranging therapeutic benefits.
While the current research was conducted in animal models, early Phase 1 trials in humans suggest that KCL-286 is safe for human use. Future studies, with adequate funding, will explore whether the drug can improve memory, thinking skills, and daily life activities in Alzheimer’s patients.
This innovative approach shifts the focus from targeting amyloid or tau proteins to repairing the brain’s underlying cellular damage. Larger clinical trials are needed to determine if this strategy will become a viable treatment option in the future.
